Treace Medical Q2 revenue tops estimates on higher surgeon adoption; ups outlook

Treace Medical Concepts,.

07/08/2026 12:16

Overview
US bunion surgery device maker's Q2 revenue fell 4% yr/yr but beat analyst expectations
Company raised full-year revenue guidance, now expecting a 4% to 0% yr/yr decline
Net loss narrowed and adjusted EBITDA loss improved from a year earlier

Outlook
Treace raises 2026 revenue guidance to $204 mln-$212 mln, down 4% to flat vs 2025
Company now expects 2026 adj EBITDA loss of $3 mln-$5 mln, vs prior $4 mln-$6 mln loss
Treace expects 2026 cash usage to decline about 50% from 2025

Result Drivers
SURGEON ADOPTION - Co said accelerating case volumes and market share gains were driven by increased surgeon adoption of its expanded bunion portfolio and new technologies
EXPENSE REDUCTIONS - Operating expenses fell 8% yr/yr, which co attributed primarily to targeted expense reduction initiatives
NEW PRODUCT LAUNCHES - Co initiated limited market release of SuperBite Compression Screw System and completed first surgical case with HyperPlate XM Dynamic Compression Locking Implant System

Company press release: ID:nGNX8qr4KT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$45.38 mln
$44.02 mln (5 Analysts)
Q2 Loss Per Share
 
$0.24
 
Q2 Gross Margin
 
78.50%
 
Q2 Gross Profit
 
$35.61 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Treace Medical Concepts, Inc. is $4.00, about 8.7% below its August 6 closing price of $4.38

Reuters Recommended Reads
Aug 4 - Alphatec Q2 revenue beats estimates on strong surgical case volume
Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand
Aug 5 - Orthofix Medical Q2 sales slightly beat estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)